Actively Recruiting

Phase Not Applicable
Age: 18Years - 90Years
All Genders
ID06071845

Assessment of a Minimally Invasive Collection Device for Molecular Analysis of Esophageal Samples for the Non-endoscopic Detection of Barrett's Esophagus With and Without Dysplasia

Led by Mayo Clinic · Updated on 2026-06-02

450

Participants Needed

5

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are evaluating the use of the Cytosponge, a minimally invasive device for collecting esophageal cells, to detect Barrett's esophagus (BE) and esophageal adenocarcinoma (EAC) in patients undergoing endoscopy. This approach combines the Cytosponge with the Oncoguard Esophagus test (OGE test), which identifies biomarkers indicating the presence of BE or EAC. The study aims to assess DNA yield from samples collected with the Cytosponge and the accuracy of the OGE test in detecting methylated DNA markers. Additionally, the study evaluates the tolerability and safety of the Cytosponge device. Participants are assigned to one of two groups: those with known or suspected BE and those without known BE. Both groups undergo the Cytosponge procedure followed by a clinically indicated sedated endoscopy using standard equipment. The Cytosponge device is administered and retrieved according to instructions, then placed in a preservative solution and sent for laboratory analysis. Participants complete surveys during the study to report tolerability and any symptoms. During the study, researchers measure DNA yield and the accuracy of the OGE test over 12 months. They also assess the tolerability of the Cytosponge device and check for any esophageal trauma within 7 days using questionnaires and endoscopic injury scores. The study includes standard endoscopic evaluations and collects participant feedback to understand the experience. The total participation period covers these assessments and follow-ups as scheduled.

CONDITIONS

Brief Title

Assessment of a Minimally Invasive Collection Device for Molecular Analysis of Esophageal Samples

Who Can Participate

Age: 18Years - 90Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adults aged 18 to 90 years
  • Subjects with known or suspected Barrett's esophagus (BE) with a BE segment of 1 cm or more or suspected BE in medical records
  • Histology showing intestinal metaplasia with or without dysplasia or suspected BE in medical records
  • Undergoing clinically indicated endoscopy
  • Subjects without known history of BE undergoing clinically indicated diagnostic endoscopy
Not Eligible

You will not qualify if you...

  • Pregnant or lactating females
  • Patients unable to consent
  • Current history of uninvestigated dysphagia
  • History of eosinophilic esophagitis or achalasia
  • Use of oral anticoagulants such as Coumadin or Warfarin
  • Use of antiplatelet agents including Clopidogrel unless stopped 3-5 days before Cytosponge procedure
  • Use of oral thrombin inhibitors like Dabigatran or factor Xa inhibitors such as rivaroxaban, apixaban, edoxaban unless stopped 3-5 days before Cytosponge procedure
  • History of esophageal or gastric varices or cirrhosis
  • History of surgical esophageal resection for esophageal carcinoma
  • Congenital or acquired bleeding disorders
  • History of esophageal squamous dysplasia
  • Known carcinoma of the foregut (pancreatic, bile duct, ampullary, stomach, duodenum) within 5 years prior to enrollment
  • Prior chemotherapy or radiation treatment for mediastinal or esophageal cancer

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Surveillance

Duration - Up to 12 months

Participants undergo sample collection with the Cytosponge device and a diagnostic sedated endoscopy to evaluate the presence of Barrett's Esophagus or related conditions.

1 visit for Cytosponge procedure and endoscopy

Long-term Monitoring

Duration - 7 days

Participants complete surveys and assessments including tolerability of the Cytosponge device and evaluation of esophageal trauma following the procedures.

1 to 2 follow-up visits

Trial Site Locations

Total: 5 locations

1

Mayo Clinic

Scottsdale, Arizona, United States, 85259

Actively Recruiting

2

Mayo Clinic in Florida

Jacksonville, Florida, United States, 32224

Actively Recruiting

3

Northwestern University

Chicago, Illinois, United States, 60611

Terminated

4

Mayo Clinic in Rochester

Rochester, Minnesota, United States, 55905

Actively Recruiting

5

Long Island Jewish Medical Center | Northwell Health

New Hyde Park, New York, United States, 11040

Completed

Loading map...

Research Team

C

Clinical Trials Referral Office

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NON_RANDOMIZED

Model

PARALLEL

Primary Purpose

SCREENING

Number of Arms

2

Similar Trials

Less-is-more in Barrett-surveillance: Care Evaluation of Bar...

Barrett Esophagus

Actively Recruiting

1 location

A Multicenter Prospective Cohort Study Comparing Random Biop...

Barrett Esophagus

Actively Recruiting

1 location

A Phase 1 Study to Evaluate the Safety and Efficacy of DISP-...

Colorectal Cancer

Actively Recruiting

3 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here